Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics

被引:299
作者
Chorny, M
Fishbein, I
Danenberg, HD
Golomb, G
机构
[1] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel
[2] Hadassah Hebrew Univ Hosp, Dept Cardiol, Jerusalem, Israel
关键词
nanospheres; nanoparticles; nanoprecipitation; controlled release; tyrphostin; drug release; formulation optimization;
D O I
10.1016/S0168-3659(02)00211-0
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
The nanoprecipitation method of nanosphere preparation offers several important advantages, such as readily adjustable and reproducible carrier size in the nanometer range and use of ingredients with low toxic potential, especially important for intravascular delivery. The applicability of the method to encapsulation of strongly lipophilic drugs has not been adequately addressed to date. In this study we applied nanoprecipitation to prepare PLA nanospheres loaded with a lipophilic tyrphostin compound, AG-1295, a potent antirestenotic agent. The effect of several formulation variables on the nanosphere basic properties (carrier size, drug release rate and drug recovery yield) was investigated. The nanosphere size was shown to be readily controlled by modifying the PLA and PLA non-solvent amounts in the organic phase. Carrier size and organic solvents' elimination rate are the main determinants of the drug release rate. The stability and drug recovery yield in the formulation depend on the drug to polymer ratio. Nanoprecipitation protocol modifications were suggested to produce nanospheres combining ultrasmall size (<100 nm) with high drug recovery yield, and to reduce the surfactant amount in the formulation. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:389 / 400
页数:12
相关论文
共 37 条
[1]
ALLEMANN E, 1996, PHARM DOSAGE FORMS D, P163
[2]
ALONSO MJ, 1996, PHARM DOSAGE FORMS D, V1, P203
[3]
PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine [J].
Banai, S ;
Wolf, Y ;
Golomb, G ;
Pearle, A ;
Waltenberger, J ;
Fishbein, I ;
Schneider, A ;
Gazit, A ;
Perez, L ;
Huber, R ;
Lazarovichi, G ;
Rabinovich, L ;
Levitzki, A ;
Gertz, SD .
CIRCULATION, 1998, 97 (19) :1960-1969
[4]
Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation [J].
Brigger, I ;
Chaminade, P ;
Marsaud, V ;
Appel, M ;
Besnard, M ;
Gurny, R ;
Renoir, M ;
Couvreur, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 214 (1-2) :37-42
[5]
Optimized preparation of poly D,L (lactic-glycolic) microspheres and nanoparticles for oral administration [J].
Chacon, M ;
Berges, L ;
Molpeceres, J ;
Aberturas, MR ;
Guzman, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 141 (1-2) :81-91
[6]
Chorny M, 2000, CRIT REV THER DRUG, V17, P249
[7]
NANOCAPSULE FORMATION BY INTERFACIAL POLYMER DEPOSITION FOLLOWING SOLVENT DISPLACEMENT [J].
FESSI, H ;
PUISIEUX, F ;
DEVISSAGUET, JP ;
AMMOURY, N ;
BENITA, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 55 (01) :R1-R4
[8]
Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis [J].
Fishbein, I ;
Chorny, M ;
Rabinovich, L ;
Banai, S ;
Gati, I ;
Golomb, G .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :221-229
[9]
Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model [J].
Fishbein, I ;
Chorny, M ;
Banai, S ;
Levitzki, A ;
Danenberg, HD ;
Gao, JC ;
Chen, X ;
Moerman, E ;
Gati, I ;
Goldwasser, V ;
Golomb, G .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (09) :1434-1439
[10]
Lidocaine-loaded biodegradable nanospheres.: I.: Optimization of the drug incorporation into the polymer matrix [J].
Görner, T ;
Gref, R ;
Michenot, D ;
Sommer, F ;
Tran, MN ;
Dellacherie, E .
JOURNAL OF CONTROLLED RELEASE, 1999, 57 (03) :259-268